logo BDSP

Base documentaire

  1. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers.

    Article - En anglais


    This population-based, nested case-control study investigated the risks of second primary cancers of the ovary, endometrium, and contralateral breast among women receiving tamoxifen for breast cancer in conventional medical practice.


    A cohort of women diagnosed with breast cancer during 1978 through 1990 was identified from a population-based cancer registry.

    Case subjects included all women in the cohort who subsequently developed second primary ovarian (n=39), endometrial (n=42), or contralateral breast (n=234) cancer prior to 1992.


    The percentage of women who had received tamoxifen was 18% and 20%, respectively, among ovarian cancer case subjects and control subjects ; 26% and 31%, respectively, among endometrial cancer case subjects and control subjects ; and 10% and 18%, respectively, among contralateral breast cancer case subjects and control subjects.

    The mean duration of tamoxifen use was less than 2 years for all groups.

    Conclusions and Implications 

    These data suggest that short durations of tamoxifen therapy are not associated with an increased risk of endometrial or ovarian cancer but are associated with a reduction in contralateral breast cancer risk.

    It would not be appropriate, however, to generalize these results to women who receive tamoxifen for longer periods.

    Mots-clés Pascal : Tumeur maligne, Glande mammaire, Ovaire, Endomètre, Controlatéral, Tamoxifène, Antioestrogène, Antihormone, Anticancéreux, Chimiothérapie, Traitement, Second cancer, Facteur risque, Epidémiologie, Washington, Etats Unis, Amérique du Nord, Amérique, Homme, Glande mammaire pathologie, Ovaire pathologie, Utérus pathologie, Appareil génital femelle pathologie, Composé non stéroïde, Etude cas témoin

    Mots-clés Pascal anglais : Malignant tumor, Mammary gland, Ovary, Endometrium, Contralateral, Tamoxifene, Antiestrogen, Antihormone, Antineoplastic agent, Chemotherapy, Treatment, Second cancer, Risk factor, Epidemiology, Washington, United States, North America, America, Human, Mammary gland diseases, Ovarian diseases, Uterine diseases, Female genital diseases, Case control study

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 96-0007309

    Code Inist : 002B20E02. Création : 01/03/1996.